Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2019 | 2 |
2020 | 1 |
2021 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
First-line checkpoint inhibitors for wild-type advanced non-small-cell cancer: a pair-wise and network meta-analysis.
Immunotherapy. 2019 Mar;11(4):311-320. doi: 10.2217/imt-2018-0107.
Immunotherapy. 2019.
PMID: 30678553
Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response.
Weng ZJ, Wu SX, Luo HS, Du ZS, Li XY, Lin JZ.
Weng ZJ, et al. Among authors: lin jz.
Inquiry. 2021 Jan-Dec;58:469580211056213. doi: 10.1177/00469580211056213.
Inquiry. 2021.
PMID: 34806458
Free PMC article.
Item in Clipboard
Front-line Therapy in Advanced Non-Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis.
Li XY, Lin JZ, Yu SH.
Li XY, et al. Among authors: lin jz.
Clin Ther. 2020 Feb;42(2):338-350.e4. doi: 10.1016/j.clinthera.2019.12.006. Epub 2020 Jan 11.
Clin Ther. 2020.
PMID: 31937461
Item in Clipboard
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Huang HW, Huang LS, Xu QN, Wang HB, Li XY, Lin JZ.
Huang HW, et al. Among authors: lin jz.
Medicine (Baltimore). 2019 Jan;98(1):e13909. doi: 10.1097/MD.0000000000013909.
Medicine (Baltimore). 2019.
PMID: 30608416
Free PMC article.
Item in Clipboard
A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?
Lin JZ, Ma SK, Wu SX, Yu SH, Li XY.
Lin JZ, et al.
Medicine (Baltimore). 2018 Jul;97(30):e11569. doi: 10.1097/MD.0000000000011569.
Medicine (Baltimore). 2018.
PMID: 30045282
Free PMC article.
Item in Clipboard
Cite
Cite